Study: Newly Identified Cannabis Compound Reduces Breast Tumor Growth and Enhances Effectiveness of Tamoxifen

A newly identified compound in cannabis has shown potential to improve breast cancer treatment, reducing tumor growth in mice and enhancing the effectiveness of tamoxifen, a widely used breast cancer medication.

Published October 25 in Biomedicine & Pharmacotherapy, the study was conducted by researchers from the Technion–Israel Institute of Technology and Heidelberg University in Germany. The compound, designated 373.15b, was found to have effects that could eventually support new approaches to treating estrogen receptor-positive breast cancer, which accounts for approximately 65% of breast cancer cases.

Researchers began by screening chemically distinct cannabis extracts to determine whether any could increase the effectiveness of tamoxifen against breast cancer cells. One extract, identified as CANN14, significantly increased the sensitivity of estrogen receptor-positive cancer cells to the medication.

Further chemical analysis allowed the team to isolate and characterize the compound responsible for much of the effect. The newly identified cannabinoid has a molecular structure distinct from familiar cannabinoids such as THC and cannabidiol (CBD), featuring a dihydroxyphenol structure with an attached acetate group.

Laboratory experiments showed that 373.15b reduced the expression and activity of estrogen receptor alpha (ERα), a protein that helps drive the growth of hormone-dependent breast cancers. The compound decreased both the genetic activity responsible for producing the receptor and the amount of receptor protein present in cancer cells.

Researchers also identified a potential mechanism involving RASSF1A and components of the Hippo signaling pathway, which help regulate cellular growth and proliferation.

Although the isolated compound did not independently produce measurable toxicity against cancer cells in the laboratory experiments, it increased their sensitivity to tamoxifen.

The team subsequently tested the cannabinoid in mice implanted with estrogen-dependent human breast cancer tumors. Treatment with 373.15b reduced tumor volume and weight, with a stronger reduction observed when the compound was administered alongside tamoxifen.

The findings are particularly relevant because tamoxifen and related medications are commonly prescribed for five to 10 years to reduce the risk of breast cancer recurrence. However, adverse effects can make long-term treatment difficult for some patients.

The study concludes by stating:

The work presented here identifies a novel cannabinoid that modulates ERα signaling and enhances the antitumor efficacy of SERMs. The findings suggests that co-therapy of 373.15b with SERMs may allow dose reduction of conventional therapy, and by that, diminish the associated adverse effects and improve patient quality of life.